Bradley Maron։ The AI Revolution in Cardiovascular Drug Development
Bradley Maron, Editor-in-Chief of Circulation at American Heart Association, shared a post on LinkedIn about a recent article by Jake Silberg, published in Circulation, adding:
”This Week in Circulation:
This week’s feature on agentic and generative AI in drug discovery is already generating real conversation — including from the authors themselves.
Dr. James Zou and colleagues discuss how AI is changing therapeutic development. They break down a complicated topic into clear terms — extremely exciting, and extremely relevant to cardiovascular medicine.
The piece walks through how AI is starting to reshape three key stages of cardiovascular drug development: target selection, therapeutic design, and clinical trial recruitment. Congratulations to Jake Silberg, Peter Eckmann, Joseph Boen, and James Zou on a piece that’s clearly striking a nerve with the field.
Here’s why it matters: the tools are early, and the authors are candid about that — but the direction of travel is one every translational scientist should be watching.”
Title: Agentic and Generative AI for Drug Discovery
Authors: Jake Silberg, Peter Eckmann, Joseph Boen, James Zou
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 04:34Hons Saurabh Kaushik: Why Uncontrolled LDL Can Be Harmful
-
Sep 20, 2026, 03:58Salih Ehsan: The Complexities of HbF and HbA2
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy
-
Sep 20, 2026, 01:04Omar Danoun: Levetiracetam May Increase Thromboembolic Risk With DOACs
-
Sep 20, 2026, 01:02Mohamed Abo-Aly: Which Antiseizure Medication is Safest for Patients on DOACs?